# A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)

> **NCT00002028** · NA · COMPLETED · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Didanosine

## Key facts

- **NCT ID:** NCT00002028
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2007-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002028, "A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00002028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*